APO-SEMAGLUTIDE INJECTION
APOTEX INC
This is a national manufacturer shortage report. It does not confirm whether the product is unavailable at your local pharmacy — call ahead or ask your pharmacist.
Quick answers
Is there a shortage of APO-SEMAGLUTIDE INJECTION in Canada?
Yes. APO-SEMAGLUTIDE INJECTION 1.34MG has an active shortage reported to Health Canada (last updated September 17, 2026).
Why is APO-SEMAGLUTIDE INJECTION not available?
The reason the manufacturer reported: Demand increase for the drug.
When will APO-SEMAGLUTIDE INJECTION be available again?
No estimated resolution date has been reported yet. Follow this page to get an email as soon as the status changes.
Ozempic and GLP-1 Shortage in Canada: Current Status
Why Ozempic and other GLP-1 medications have cycled in and out of shortage in Canada, how to check the current status, and what to ask your pharmacist if yours is affected.
Other Products Containing the Same Active Ingredient
These are other Health Canada-approved human drug products containing the same active ingredient, not currently reported in shortage. Strength, dosage form, and route can still differ — ask your pharmacist whether any of these are appropriate for you. This isn't a guarantee of current stock.
Closest Matches
SANDOZ SEMAGLUTIDE
SANDOZ CANADA INCORPORATED
ASPEN-SEMAGLUTIDE
ASPEN PHARMACARE CANADA INC.
PLOSBRIO
NOVO NORDISK CANADA INC
Other Products
WEGOVY
NOVO NORDISK CANADA INC
OZEMPIC
NOVO NORDISK CANADA INC
What this means
Does this mean my pharmacy is out of stock?
Not necessarily — a national shortage doesn't mean every pharmacy has run out. Some locations may still have stock, especially of a specific strength or pack size.
What should I do?
Contact your pharmacy before your current supply runs low, and ask your pharmacist about next steps if they're out.
⚠ Possible Recall or Safety Alert
Health Canada has issued a recall or safety alert matching this product. This match is based on product name similarity and may not be exact — confirm against your specific lot number before taking action.
Apo-Semaglutide Injection
Apo-Semaglutide Injection : Incorrect dose display
Moderate health risk
Possible match — not confirmed
Apo-Semaglutide
Apo-Semaglutide Injection : Incorrect dose display
Moderate health risk
Possible match — not confirmed
Semaglutide Injection
Semaglutide Injection : Out-of-Specification (Impurity)
Moderate health risk
Possible match — not confirmed
Semaglutide Injection
Semaglutide Injection: Incorrect Pen in Package
Moderate health risk
Possible match — not confirmed
DIN
02568012
Strength
1.34MG
Dosage Form
SOLUTION
Route
SUBCUTANEOUS
Compare with another product →
Shortage Timeline
Approximate — based on the dates HPSC reports were last updated, not confirmed onset or resolution dates. Gaps between bars are periods with no shortage on file.
Shortage History
Other Products from APOTEX INC
Other Health Canada-approved products made by the same manufacturer — not necessarily related to this shortage, and not necessarily in shortage themselves.
50MCG · DIN 02460513
325MG · DIN 02362341
500MG · DIN 02362368
DIN 02290901
325MG · DIN 02362422
500MG · DIN 02362244
10MG · DIN 02240414
20MG · DIN 02296098
150MG · DIN 02296160
75MG · DIN 02230507
2MG · DIN 02554194
2MG · DIN 02554178